PolyNovo Limited (ASX:PNV)
Australia · Delayed Price · Currency is AUD | Market Cap | 690.84M -6.1% |
| Revenue (ttm) | 139.49M +20.7% |
| Net Income | 9.88M +67.3% |
| EPS | 0.01 +67.6% |
| Shares Out | 690.84M |
| PE Ratio | 71.07 |
| Forward PE | 46.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,527,129 |
| Average Volume | 1,844,179 |
| Open | 1.0000 |
| Previous Close | 1.0050 |
| Day's Range | 0.9800 - 1.0050 |
| 52-Week Range | 0.8650 - 1.7150 |
| Beta | 1.29 |
| RSI | 50.57 |
| Earnings Date | May 21, 2026 |
About PolyNovo
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to tre... [Read more]
Financial Performance
In fiscal year 2025, PolyNovo's revenue was 128.70 million, an increase of 24.67% compared to the previous year's 103.23 million. Earnings were 13.21 million, an increase of 151.17%.
Financial StatementsNews
PolyNovo Earnings Call Transcript: H1 2026
Group sales rose 26% to AUD 68.2 million, led by strong U.S. and international growth, with Adjusted EBITDA up 82%. Manufacturing capacity expanded, clinical evidence base strengthened, and new markets targeted for further acceleration.
PolyNovo Transcript: AGM 2025
The meeting highlighted strong financial growth, global expansion, and robust product innovation, while addressing governance reforms and executive turnover. Shareholders raised concerns about board practices and share price volatility, with the company emphasizing ongoing governance improvements and strategic investments.
PolyNovo Earnings Call Transcript: H2 2025
Record sales and profit growth were driven by strong U.S. and international demand, new product launches, and operational leverage. Cash flow and margins improved, with continued expansion into new markets and indications expected to sustain momentum.
PolyNovo Earnings Call Transcript: H2 2025
Strong global sales growth continues, led by the U.S. and supported by new product launches and international expansion. Cash position and profitability have improved, with no need for additional capital raising. Record monthly revenue and ongoing innovation support a positive outlook.
PolyNovo Transcript: Investor Update
Sales and cash flow remain strong, with robust growth in the U.S. and India. New product MTX is gaining traction, and the Betacell platform shows promise for cell therapy applications, positioning the business for expansion in both wound care and cell delivery.
PolyNovo Earnings Call Transcript: H1 2025
Revenue rose 22.8% to AUD 59.9 million, with strong growth in the U.S. and Europe and MTX gaining traction. Net profit after tax increased to AUD 3.3 million, and new product launches and capacity expansion are on track to support multi-year growth.
PolyNovo Transcript: AGM 2024
AGM highlighted robust financial growth, global expansion to 42 countries, and strong humanitarian impact. Key resolutions passed, manufacturing and R&D capacity are scaling, and the board is enhancing governance with new policies and skills assessment.
PolyNovo Earnings Call Transcript: H2 2024
Revenue grew 57% to AUD 104.8 million with first full-year profit of AUD 5.3 million. U.S. and global expansion drove record sales, while new product innovations and a major India tender set up future growth. Gross margin remained strong at 94%.